Regeneron Pharmaceuticals Inc. ($REGN) Stock Forecast: Up 5.6% Today

What is Regeneron Pharmaceuticals Inc.?

Regeneron Pharmaceuticals, Inc. (REGN) is a biotechnology company known for its innovative approach to developing medicines for serious diseases. Today, REGN experienced a strong bullish movement in the market.

Why is Regeneron Pharmaceuticals Inc. going up?

REGN stock is up 5.6% on Dec 11, 2025 15:01

• Intact Investment Management Inc. significantly increasing its stake in REGN indicates growing confidence in the company's future prospects, potentially contributing to the bullish movement.
• Positive early data on Regeneron's Lynozyfic monotherapy for multiple myeloma patients showcases the company's promising developments in the oncology sector, boosting investor sentiment.
• Increasing the price target for REGN reflects optimism in the company's performance, aligning with the overall bullish trend in the market.
• The strong performance of AbbVie and Genmab's Epkinly at the ASH Annual Meeting may have positively influenced the biotech sector as a whole, indirectly benefiting companies like Regeneron.

REGN Price Chart

REGN Technical Analysis

REGN News

Scotiabank Sticks to Their Buy Rating for AbbVie (ABBV)

Scotiabank analyst Louise Chen has reiterated a Buy rating for AbbVie (ABBV) with a price target of $280.00. This follows AbbVie's recent Q3 earnings report, which showed $15.78 billion in revenue. Other analysts have offered mixed ratings, with HSBC issuing a Buy and TR | OpenAI – 4o maintaining a Hold.

https://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/36569393/scotiabank-sticks-to-their-buy-rating-for-abbvie-abbv/

Intact Investment Management Inc. Grows Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Intact Investment Management Inc. significantly increased its stake in Regeneron Pharmaceuticals, Inc. (REGN) by 192.3% during the second quarter, bringing its total holdings to 2,280 shares valued at $1,197,000. Other institutional investors also modified their positions in REGN, which reported strong quarterly earnings and a recent dividend announcement. The company currently holds a "Moderate Buy" rating from analysts with an average target price of $779.41.

https://www.marketbeat.com/instant-alerts/filing-intact-investment-management-inc-grows-holdings-in-regeneron-pharmaceuticals-inc-regn-2025-12-11/

How Investors May Respond To Regeneron (REGN) Lynozyfic Multiple Myeloma Data And Frontline Oncology Ambitions

Regeneron Pharmaceuticals' Lynozyfic (linvoseltamab) monotherapy shows strong early data in newly diagnosed multiple myeloma patients, indicating its potential as a frontline treatment. While these results bolster Regeneron's oncology ambitions and pipeline, the company's investment narrative still largely depends on offsetting EYLEA competition with new blockbusters and diversified revenue streams. Investors must weigh the promising oncology developments against ongoing challenges in its established markets.

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-regn/regeneron-pharmaceuticals/news/how-investors-may-respond-to-regeneron-regn-lynozyfic-multip

Wells Fargo Raises Price Target for Regeneron (REGN) to $745 | R

Wells Fargo has updated its price target for Regeneron Pharmaceuticals (REGN) from $700 to $745, while maintaining an Equal-Weight rating. This adjustment reflects a 6.43% increase in their price expectation amidst a flurry of other analyst updates with varying ratings and price targets. The average target price from 29 analysts stands at $780.40, suggesting an 8.32% upside from the current price.

https://www.gurufocus.com/news/3241592/wells-fargo-raises-price-target-for-regeneron-regn-to-745-regn-stock-news

ASH 2025: AbbVie and Genmab’s Epkinly sets new standard in second-line FL

At the American Society of Hematology (ASH) Annual Meeting, AbbVie and Genmab's Epkinly, in combination with Revlimid and Rituxan, demonstrated significantly improved response rates and progression-free survival in relapsed/refractory follicular lymphoma. This triple therapy achieved an overall response rate of 95% and reduced the risk of progression or death by 79% compared to standard-of-care, setting a new benchmark for second-line treatment. The FDA has already approved this regimen, and Epkinly's global sales are projected to reach $2.6 billion by 2031, outperforming competitors in the R/R FL landscape.

https://finance.yahoo.com/news/ash-2025-abbvie-genmab-epkinly-174042457.html

Trending Today

Beyond Meat Inc. ($BYND) Stock Forecast: Up 5.7% Today

Comcast Corporation Class A Common Stock ($CMCSA) Stock Forecast: Up 5.0% Today

National Oilwell Varco Inc. ($NOV) Stock Forecast: Down 5.1% Today

Phillips 66 ($PSX) Stock Forecast: Down 5.1% Today

Pfizer Inc. ($PFE) Stock Forecast: Down 5.1% Today

Humana Inc. ($HUM) Stock Forecast: Down 5.1% Today

Cytokinetics, Incorporated ($CYTK) Stock Forecast: Down 5.0% Today

S&P 500 Index ($SPX) Index Forecast: Down 0.8% Today

Apache Corporation ($APA) Stock Forecast: Down 5.1% Today

Wix.com Ltd. ($WIX) Stock Forecast: Up 5.1% Today

Regeneron Pharmaceuticals Inc. Price History

30.04.2025 - REGN Stock was down 18.4%

• Mixed results from late-stage COPD studies conducted by Regeneron and SNY could have led to investor uncertainty and a sell-off of REGN shares.
• Meeting the primary endpoint in one trial but missing in another may have raised concerns about the drug's overall effectiveness and potential market approval.
• The uncertainty surrounding future plans for itepekimab in treating COPD could have contributed to the bearish market movement of REGN today.

18.08.2025 - REGN Stock was down 0.1%

• Despite promising results from a Phase 3 study on Garetosmab demonstrating a notable decrease in new bone lesions and favorable tolerability, the stock's decline may be linked to factors like general market sentiment or profit-taking.
• Concerns among investors may stem from the anticipation of a Wall Street trader's upcoming strategy unveiling, leading to apprehension and selling pressure on REGN shares.
• The drop in stock value may also reflect broader industry patterns or external market conditions affecting biotech stocks, resulting in a retreat in Regeneron's stock price.

01.07.2025 - REGN Stock was down 1.9%

• The stock had a bearish movement as analysts are expecting lower Q2 earnings compared to the year-ago period.
• The anticipated decrease in quarterly earnings to $8.43 per share, down from $11.56 per share, likely contributed to the bearish trend.
• Despite the long-term outperformance of Regeneron Pharmaceuticals, short-term concerns about earnings may have led to the negative market movement.
• Investors may be reacting to the revised forecasts ahead of the earnings call, causing a dip in the stock price.

28.09.2025 - REGN Stock was up 6.5%

• The upcoming Q3 earnings report for Regeneron is expected to focus on the performance of Dupixent and Eylea sales.
• Investors are optimistic about the potential of higher profits from Dupixent offsetting any decline in Eylea sales.
• The strong uptake of Eylea HD amid competition is also a key factor driving positive sentiment towards REGN stock.
• Overall, the market seems to be reacting positively to the potential growth prospects highlighted in the upcoming earnings report, leading to the bullish movement in REGN stock.

02.11.2025 - REGN Stock was down 5.7%

• The bearish movement in REGN's stock today can be attributed to Quadrant Capital Group LLC selling 688 shares, reducing its stake in the company by 25.6%. This sell-off might have created a negative sentiment among investors, leading to a decline in the stock price.
• Despite surpassing earnings expectations and maintaining strong profitability, REGN's stock underperformed on a day when the overall market, as represented by the S&P 500 Index and Dow Jones Industrial Average, also experienced losses. This broader market trend could have contributed to the downward pressure on REGN's stock.
• The partnership with Tessera Therapeutics to develop a gene-editing therapy for a rare disorder highlights REGN's commitment to innovation. However, heightened competition and potential regulatory delays mentioned in recent sources may have raised concerns among investors, impacting the stock price negatively.
• The overall positive outlook on REGN, with analysts rating it a "Moderate Buy" and the company announcing a quarterly dividend, suggests that the bearish movement today could be a short-term correction amidst a backdrop of long-term growth potential.

08.04.2025 - REGN Stock was down 6.5%

• The stock price of Regeneron Pharmaceuticals experienced a significant decline today, despite a slight increase in the current market session.
• The downward trend in the stock price could be attributed to the overall market sentiment affecting biotech and pharmaceutical companies.
• Investors might be reacting to the stock's performance over the past month and year, where it has shown a notable decrease, possibly leading to profit-taking or market corrections.
• While Regeneron Pharmaceuticals has historically outperformed the market over the long term, short-term fluctuations can be influenced by various factors, including industry news and market conditions.

06.04.2025 - REGN Stock was down 5.1%

• REGN stock's decline could be linked to profit-taking following a period of market outperformance.
• Investor sentiment may be influenced by negative developments or uncertainties related to Regeneron Pharmaceuticals.
• Overall market trends or sector-specific factors might have contributed to REGN stock's downward trajectory.
• The decrease in Regeneron Pharmaceuticals' stock value could be a result of investors reallocating their investments to alternative opportunities.

11.11.2025 - REGN Stock was up 5.6%

• Intact Investment Management Inc. significantly increasing its stake in REGN indicates growing confidence in the company's future prospects, potentially contributing to the bullish movement.
• Positive early data on Regeneron's Lynozyfic monotherapy for multiple myeloma patients showcases the company's promising developments in the oncology sector, boosting investor sentiment.
• Increasing the price target for REGN reflects optimism in the company's performance, aligning with the overall bullish trend in the market.
• The strong performance of AbbVie and Genmab's Epkinly at the ASH Annual Meeting may have positively influenced the biotech sector as a whole, indirectly benefiting companies like Regeneron.

10.05.2025 - REGN Stock was up 5.1%

• The bullish movement in REGN stock today can be attributed to the positive news of expanding its pipeline through a strategic deal in the obesity drug market. Investors seem optimistic about the company's efforts to address challenges in its existing portfolio and capitalize on new opportunities for growth, leading to increased confidence and buying interest in the stock.

29.03.2025 - REGN Stock was down 10.1%

• The bearish movement in REGN today could be attributed to investor concerns about the upcoming Q1 earnings.
• The focus on the performance of key drugs like Dupixent and Eylea HD may have led to uncertainty and profit-taking among investors.
• The market might be reacting to any potential signs of underperformance or lower-than-expected sales figures for these key products.
• Investors may be adjusting their positions in anticipation of the earnings, leading to the bearish movement in REGN today.

30.03.2025 - REGN Stock was up 5.5%

• Regeneron Pharmaceuticals Inc. (REGN) experienced a strong bullish movement today.
• The positive market sentiment could be attributed to potential breakthroughs in the company's research and development pipeline, driving investor confidence in its future prospects.
• Investors may also be reacting to favorable regulatory developments or promising clinical trial results, further boosting REGN's stock price.
• Overall, the bullish movement in REGN reflects growing optimism in the biotechnology sector and the company's ability to deliver innovative solutions to pressing healthcare challenges.

01.09.2025 - REGN Stock was up 5.3%

• The momentum could be linked to the FDA's approval for the label extension of REGN's cholesterol drug Evkeeza, permitting its usage in children as young as one suffering from severe familial hypercholesterolemia.
• The FDA's endorsement for expanding the utilization of Regeneron's Evkeeza to infants with a rare cholesterol disorder may have instilled confidence in investors regarding the company's pipeline and prospective revenue.
• Anticipation surrounding Regeneron's forthcoming third-quarter financial and operating results announcement might also be fostering optimism among investors, who foresee strong performance and growth opportunities.